Daxor

Daxor Gross Margin

The Gross Margin of Daxor (DXR) as of Oct 16, 2026 is 37.49 %. In the previous year, Gross Margin was 100.00 % — a change of -62.51% (lower).

Gross Margin

37.49 %

YoY

-62.51%

Last updated:

Gross Margin of Daxor is 2025 37.49 % . Gross Margin of Daxor was 2024 100.00 % . It decreases by -62.51% lower compared to the previous year.

For Daxor, the gross margin of 37.5% is down versus 100.0% a few years ago.

The Daxor Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
100.00 USD
Jan 1, 2019
100.00 USD
Jan 1, 2020
100.00 USD
Jan 1, 2021
100.00 USD
Jan 1, 2022
100.00 USD
Jan 1, 2023
99.49 USD
Jan 1, 2024
100.00 USD
Jan 1, 2025
37.49 USD
The Daxor Gross Margin history
YEARGross MarginYoY
37.49 %-62.51%
100.00 %+0.51%
99.49 %-0.51%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %0.00%
100.00 %+17.76%
84.92 %-18.52%
104.23 %+4.23%
100.00 %+9,900.00%
1.00 %0.00%
1.00 %+104.42%
0.49 %-9.28%
0.54 %-7.45%
0.58 %-17.59%
0.71 %-5.17%
0.75 %+20.36%
0.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Daxor Stock analysis

What does Daxor do? Daxor Corp, listed on the ticker DXR with ISIN US2394671034, is a health care company based in New York City, United States. The company went public on July 25, 1983. Daxor Corp develops and manufactures the BVA-100 blood volume analyzer, a diagnostic instrument cleared by the U.S. Food and Drug Administration (FDA). This device measures human blood volume and provides objective quantification of blood volume status and composition relative to patient-specific norms. The company reports that over 65,000 tests have been conducted at hospital centers across the United States. These tests are associated with improvements in hospital performance metrics for various surgical and medical conditions, including reductions in mortality and readmissions for heart failure and critical care patients. Daxor Corp is engaged in advancing healthcare through blood volume analysis, focusing on optimal fluid management. The company is conducting ongoing clinical trials related to heart failure treatment, supported by the National Institutes of Health (NIH), and is also under contract to develop additional analyzers. The company's website is https://www.daxor.com/. Daxor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Daxor stock

Gross Margin of Daxor is 37.49 % in 2025.

Gross Margin of Daxor changed from 100.00 % to 37.49 %, representing a -62.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Daxor since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Daxor with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Daxor

All Key Metrics — Daxor